Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Syncona CEO On Why Its 10th Start-Up Focuses On T-Regulatory Cell Therapies

Executive Summary

UK investment group Syncona Ltd has financed its tenth start-up, Quell Therapeutics, with the aim of developing engineered T regulatory (Treg) cell therapies.

You may also be interested in...



Finance Watch: Big Bucks For T-regs In Autoimmune Diseases, Inflammation

GentiBio closed a $157m series A venture capital round, while clinical trial innovator Reify Health raised a $220m series C and Neurelis secured $150m. Also, IPOs slowed in August, but Adagio and Eliem grossed $309.4m and $80m, respectively, and RNA firm Greenlight will go public in a $282m SPAC deal. 

UK Firms Big And Small Benefit From Biotech Bubble

Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.

Syncona Focuses On Creating Commercially Ambitious Businesses

With £1bn under management, patient capital company Syncona Limited reveals its strategy for creating and building companies that will generate reimbursable products for patients.

Topics

UsernamePublicRestriction

Register

SC125261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel